Immunogenicity Summit
  • Slide 1
  • Slide 2
  • Slide 3

About the Summit

Get ready to join 300+ of your peers on November 11-13, 2013 in Washington, DC at the Number 1 Immunogenicity Summit in the U.S. CHI has an established reputation as a global education provider on immunogenicity. Our 2013 summit will build on last year’s successful event. With double the number of tracks this year, the Immunogenicity Summit 2013 presents technologies for safety and efficacy from bench to bedside. For early stage decision making on drug design and optimization, we examine the causes of immunogenicity together with means of mitigation, and present PKPD and bioassay strategies. For later pre-clinical and clinical stages, we examine the complexities of immunogenicity assays, bioassays and PKPD development, and present risk assessment strategies for smooth interaction with the regulatory authorities, and safe and efficacious products in the clinic.

We are now accepting speaker proposals for our 2013 summit. Submit your speaker proposal today if you are interested in sharing your research with an international audience.

Short Courses

November 10
  • Technical Advice on Assay Development, Validation and Sample Analysis
  • Development of Neutralizing Antibody Assays (Dinner Course)
  • Navigating the Regulatory Hierarchy of Concerns to Minimize Impact of Immunogenicity-Related Risks on Product Registration
 

Event Features

  • Access All 4 Conferences for One Price
  • Network with 300+ Global Attendees
  • Hear 50+ Scientific Presentations
  • Learn from FDA, Industry, and Leading Academic Research Centers
  • Dedicated Exhibit/Poster Viewing
  • Choose from 3 Pre-Conference Short Courses
  • Interactive Roundtable, Breakout & Panel Discussions
  • Dedicated Networking Opportunities
 

What Your Peers Have to Say
About This Event:

Congratulations on a very well put together conference. 

    - Assistant Vice President, Pfizer

Program and participants, first class. 

    - Associate Director, Novo Nordisk

I’m glad I attended the PK/PD meeting. Nowhere else could I find a conference entirely devoted to the in vivo activity of novel constructs. 

    - Principal Scientist, Amgen

You have succeeded in attracting the very best speaker panel I have ever seen to a meeting of this nature. 

    - Advisor, NDA Advisory Board.

Break-out interaction with FDA experts was very valuable. 

    - Associate Director, Alexion
      Pharmaceuticals Inc.